SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis
Copyright © 2022 Elsevier Ltd. All rights reserved..
BACKGROUND: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine.
PATIENTS AND METHODS: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression.
RESULTS: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10-0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11-0.35).
CONCLUSIONS: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
Journal of autoimmunity - 132(2022) vom: 05. Okt., Seite 102906 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Autoimmunity |
|---|
| Anmerkungen: |
Date Completed 22.11.2022 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaut.2022.102906 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346058686 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346058686 | ||
| 003 | DE-627 | ||
| 005 | 20231226030525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaut.2022.102906 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1153.xml |
| 035 | |a (DE-627)NLM346058686 | ||
| 035 | |a (NLM)36088883 | ||
| 035 | |a (PII)S0896-8411(22)00114-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Efe, Cumali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine | ||
| 520 | |a PATIENTS AND METHODS: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression | ||
| 520 | |a RESULTS: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10-0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11-0.35) | ||
| 520 | |a CONCLUSIONS: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Autoimmunity | |
| 650 | 4 | |a Breakthrough infection | |
| 650 | 4 | |a Immunosuppression | |
| 650 | 4 | |a Liver failure | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 700 | 1 | |a Taşçılar, Koray |e verfasserin |4 aut | |
| 700 | 1 | |a Gerussi, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Bolis, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Lammert, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Ebik, Berat |e verfasserin |4 aut | |
| 700 | 1 | |a Stättermayer, Albert Friedrich |e verfasserin |4 aut | |
| 700 | 1 | |a Cengiz, Mustafa |e verfasserin |4 aut | |
| 700 | 1 | |a Gökçe, Dilara Turan |e verfasserin |4 aut | |
| 700 | 1 | |a Cristoferi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Peralta, Mirta |e verfasserin |4 aut | |
| 700 | 1 | |a Massoumi, Hatef |e verfasserin |4 aut | |
| 700 | 1 | |a Montes, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Cerda, Eira |e verfasserin |4 aut | |
| 700 | 1 | |a Rigamonti, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Yapalı, Suna |e verfasserin |4 aut | |
| 700 | 1 | |a Adali, Gupse |e verfasserin |4 aut | |
| 700 | 1 | |a Çalışkan, Ali Rıza |e verfasserin |4 aut | |
| 700 | 1 | |a Balaban, Yasemin |e verfasserin |4 aut | |
| 700 | 1 | |a Eren, Fatih |e verfasserin |4 aut | |
| 700 | 1 | |a Eşkazan, Tuğçe |e verfasserin |4 aut | |
| 700 | 1 | |a Barutçu, Sezgin |e verfasserin |4 aut | |
| 700 | 1 | |a Lytvyak, Ellina |e verfasserin |4 aut | |
| 700 | 1 | |a Zazueta, Godolfino Miranda |e verfasserin |4 aut | |
| 700 | 1 | |a Kayhan, Meral Akdogan |e verfasserin |4 aut | |
| 700 | 1 | |a Heurgue-Berlot, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a De Martin, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Yavuz, Ahmet |e verfasserin |4 aut | |
| 700 | 1 | |a Bıyık, Murat |e verfasserin |4 aut | |
| 700 | 1 | |a Narro, Graciela Castro |e verfasserin |4 aut | |
| 700 | 1 | |a Duman, Serkan |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez, Nelia |e verfasserin |4 aut | |
| 700 | 1 | |a Gatselis, Nikolaos K |e verfasserin |4 aut | |
| 700 | 1 | |a Aguirre, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Idilman, Ramazan |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Marcelo |e verfasserin |4 aut | |
| 700 | 1 | |a Mendizabal, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Atay, Kadri |e verfasserin |4 aut | |
| 700 | 1 | |a Güzelbulut, Fatih |e verfasserin |4 aut | |
| 700 | 1 | |a Dhanasekaran, Renumathy |e verfasserin |4 aut | |
| 700 | 1 | |a Montano-Loza, Aldo J |e verfasserin |4 aut | |
| 700 | 1 | |a Dalekos, George N |e verfasserin |4 aut | |
| 700 | 1 | |a Ridruejo, Ezequiel |e verfasserin |4 aut | |
| 700 | 1 | |a Invernizzi, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Wahlin, Staffan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of autoimmunity |d 1989 |g 132(2022) vom: 05. Okt., Seite 102906 |w (DE-627)NLM012637491 |x 1095-9157 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2022 |g day:05 |g month:10 |g pages:102906 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaut.2022.102906 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2022 |b 05 |c 10 |h 102906 | ||